Heading block <h1>

Heading block <h2> short introduction lorem ipsum dolor sit amet dantes eras.

Content area block (WYSIWYG).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Content area two columns.

Content area two columns.

This is a quote lorem ipsum dolor sit amet dantes eras sedum

Quote Attribution
Featured content columns

Column 1 heading

Column 1 sub-heading

Link goes here
Column 1 heading
Action panel

Padding – none / Margins – both

Featured content columns – column 1

Content lorem ipsum dolor sit amet dantes sedum eras.

Link goes here

Featured content columns – column 2

Content lorem ipsum dolor sit amet dantes sedum eras.

link goes here

Featured content columns – column 3

Content lorem ipsum dolor sit amet dantes sedum eras.

link goes here
Action panel

Padding – none / Margins – top

Action panel

Padding – none / Margins – top

Featured content columns – column 1

Content lorem ipsum dolor sit amet dantes sedum eras.

Link goes here

Featured content columns – column 2

Content lorem ipsum dolor sit amet dantes sedum eras.

link goes here

Featured content columns – column 3

Content lorem ipsum dolor sit amet dantes sedum eras.

link goes here
Key benefits list

Affimer biotherapeutics have a number of essential advantages over other technologies, such as antibodies and aptamers.

Small & stable

Small & stable

Affimer proteins are 12-14 kDa in size – approximately 10 times smaller than an antibody. This small size combined with their stability profile and their human origin confer good drug-like properties to Affimer molecules. This can represent a significant advantage over antibodies in terms of tissue penetration, for example in solid tumours or for non-invasive topical administration such as inhaled delivery or dermal application.

Easy to engineer & format

Easy to engineer & format

Because they are single polypeptide chains, Affimer molecues can be engineered and fused to a variety of different proteins to develop innovative biotherapeutics with a broad range of useful characteristics. Several Affimer molecules can be fused together to create multispecific molecules that can target and recruit specific cells (e.g. T-cells). They can be fused to Fc fragments or albumin binders to tune their in vivo half-life depending on the desired mechanism of action and therapeutic window. They can potentially be used as the targeting moiety in chimeric receptors or be modified to carry a toxin in Affimer-drug conjugates.

Applications list

A text introduction can go here before the application list.

Immunco-oncology

Immunco-oncology

Monotherapies to a broad range of dirrefermt targets More

Affimer therapeutics can be developed as monotherapies to a broad-range of different targets. We currently have several internal programmes focusing on immuno-oncology targets, as well as partnered and collaborative programmes focusing on blood clotting disorders and infectious diseases.

Multi-specific targeting

Multi-specific targeting

Building blocks for multi-domain proteins More

The Affimer scaffold can be used as a building block to form larger multi-domain proteins, comprising of several Affimer binders. At the simplest level the same Affimer sequence can be repeated several times to create a molecule that has enhanced binding affinity (via avidity effects), if the target is also multimeric. If the target is a cell surface receptor, then an Affimer dimer can be used to cross-link receptors and cause agonism.rnrnBy genetically linking Affimer proteins together that recognise different targets, a multi-specific format can be created. If the targets are cell surface proteins on two different cell types, then an Affimer bi-specific protein could be used to bring two different cells together. This approach is particularly important in oncology, because with the right target combination it allows T-cells to be redirected to the tumour to enhance cell killing.

Staff Profile Grid

GROUP NAME
Alastair Smith

Alastair Smith

Chief Executive Officer
Biography

TMAC Programme Accelerates: Clinical Trial Planned for Early 2020

Alastair is Chief Executive of Avacta Group plc.

He has been responsible for the management and strategic development of the company and has led the public and private M&A activities of the Group since the IPO on AIM which was completed via a reverse merger in 2006. Alastair is a respected and trusted executive with many years experience of investor relations in the UK, Europe and US and has successfully delivered multiple follow-on fundraisings for the Group totalling over £120m.

Avacta Group is developing next generation oncology drugs based on its proprietary Affimer® and preCISIONTM platforms through its clinical stage Therapeutics Division based in Cambridge, UK. Its Diagnostics Division, based in Wetherby, UK, is developing a pipeline of diagnostic immunoassays utilising Affimer® reagents and works with partners world-wide to develop Affimer-powered products. The Group has around one hundred employees across its two sites and a business development team in the US.

He has a degree and PhD in Physics from Manchester University and, following a period of working in the US, took up a position at Leeds University in 1995. At the age of 38 he was awarded a Chair of Molecular Biophysics and had, over ten years, grew one of the leading biophysics research groups in Europe before he left his academic career in 2007 to focus full time on delivering value to Avacta shareholders.

Resources section

Here is some introductory text